Supernus Pharmaceuticals Closes two Transactions to Raise $42 Million

"We have been able to raise more than $165 million through a series of five non-dilutive financing transactions that have enabled us to progress two epilepsy product candidates into NDA stage and two other product candidates in the ADHD area into Phase II. Since its inception six years ago, and despite the continued challenging financing environment, Supernus has developed a broad and diversified portfolio of product candidates that provides us with multiple opportunities to achieve our goal of becoming a leading CNS specialty pharmaceutical company," said Jack Khattar, President and Chief Executive Officer.